Opioid-related Lawsuits and Non-Infringement Ruling
Here’s what could influence ENDP’s performance in the coming months: In addition, several lawsuits that ENDP is battling could foster bearish investor sentiment. Although the company’s impressive sequential growth driven by the XIAFLEX pharmaceutical brand in the last reported quarter and advancements in the growth of its product pipeline should bode well for the stock, its operational losses have expanded significantly. The stock is currently trading 80.6% below its 52-week high of $10.89, which it hit on February 18. Shares of ENDP have tumbled 4.8% in price over the past five days and 49.4% over the past month because of its plans to explore a potential financial restructuring.Īs reported by The Wall Street Journal, the company is said to have hired a financial restructuring advisor prompted by a flood of opioid-related lawsuits. Ireland-based specialty pharmaceutical company Endo International plc ( ENDP ) manufactures and sells generic and branded pharmaceuticals in the United States and worldwide. So, although the company remains committed to expanding its product pipeline, can the stock rebound given the company’s recent loss in a patent fight over its bestselling drug? Let’s discuss.
Shares of specialty pharmaceutical company Endo International (ENDP) have plunged in price over the past month owing to news that the drugmaker is evaluating financial restructuring options to deal with several opioid-related lawsuits.
0 kommentar(er)
